This product will be manufactured at Lupin’s Nagpur facility in India and will be supplied to low and middle-income countries
The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms over 12 weeks compared to placebo
Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection
The drug will be marketed in different strengths of 150 mg and 440 mg and used in the treatment of patients with HER2
BAV has revolutionized the animal vaccination industry with its ground-breaking delivery methods that prioritize quality, safety, and efficacy
Decision on EU marketing authorisation for this population expected by September 2024
GSK and Flagship to jointly fund up to $150 million upfront
The partnership will significantly advance their sustainability initiatives by meeting around 67% of their power requirements for these plants
This strategic move aims to make Cupid's high-quality products more accessible to consumers nationwide
The discussion at the fourth session was centered on the fusion of academic rigor and industrial pragmatism as a key to pioneering solutions for sustainable and prosperous future
Subscribe To Our Newsletter & Stay Updated
